Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit?

Author： Clozel Martine  

Publisher： Informa Healthcare

ISSN： 0785-3890

Source： Annals of Medicine, Vol.35, Iss.8, 2003-12, pp. : 605-613

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-term trial of bosentan monotherapy for pulmonary arterial hypertension in Japanese patients

By Sasayama Shigetake   Satoh Toru   Izumi Tohru   Yoshida Shunji   Kyotani Shingo   Tahara Nobuhiro  

Current Medical Research and Opinion, Vol. 23, Iss. 2, 2007-02 ,pp. : 395-400

Informa Healthcare

Access to resources Recommend Favorite

Long-Term Bosentan in Chronic Thromboembolic Pulmonary Hypertension

By  

Respiration, Vol. 74, Iss. 3, 2006-05 ,pp. : 287-292

Karger

Access to resources Recommend Favorite

Efficacy and Safety of Long-Term Imatinib Therapy for Pulmonary Arterial Hypertension

By  

Respiration, Vol. 89, Iss. 6, 2015-06 ,pp. : 515-524

Karger

Access to resources Recommend Favorite

Long-Term Inhaled Nitric Oxide plus Dipyridamole for Pulmonary Arterial Hypertension

By  

Respiration, Vol. 72, Iss. 4, 2005-07 ,pp. : 419-422

Karger

Access to resources Recommend Favorite

Bosentan for treatment of pulmonary arterial hypertension (I)

By Antoniu Sabina A  

Therapy, Vol. 2, Iss. 6, 2005-11 ,pp. : 843-847

Future Medicine

Access to resources Recommend Favorite